Inhibikase Therapeutics Inc (IKT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $213.21M
Last updated: Nov 17, 2026 at 11:06 AM ET
Inhibikase Therapeutics Inc (IKT) Stock Forecast
Analysts expect Inhibikase Therapeutics (IKT) to earn -$0.40 per share in the fiscal year ending Dec 31, 2026, on revenue of $250000. Of 10 analysts, 9 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 90% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 10.0% |
| Buy | 8 | 80.0% |
| Hold | 1 | 10.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 60.0%.
- Fiscal year ending Dec 31, 2026
- -$0.40
- EPS consensus, revenue $250000
- Fiscal year ending Dec 31, 2027
- -$0.41
- EPS consensus, revenue $400000
- Next report
- Mar 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.40 | -$0.42 to -$0.38 | 2 | $250000 | N/A | 6 |
| Dec 31, 2027 | -$0.41 | -$0.45 to -$0.37 | 5 | $400000 | N/A | 5 |
Quarterly Estimates
The EPS consensus is -$0.11 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.11 | -$0.16 to -$0.06 | 10 | $252500 | N/A | 10 |
| Mar 31, 2027 | -$0.11 | -$0.12 to -$0.09 | 2 | N/A | N/A | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.44.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.40 | -$0.40 | -$0.40 | -$0.45 | -$0.44 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.41 | -$0.42 | -$0.42 | -$0.43 | -$0.42 | N/A |
| Quarter ending Mar 31, 2027 | -$0.11 | -$0.11 | -$0.11 | -$0.13 | -$0.13 | N/A |
Frequently Asked Questions About IKT
What is the IKT stock forecast?
Consensus analyst estimates put Inhibikase Therapeutics's EPS at -$0.40 for the fiscal year ending Dec 31, 2026, on revenue of $250000. The consensus rating from 10 analysts is Buy.
How do analysts rate IKT stock?
Of 10 analysts covering Inhibikase Therapeutics, 1 rates it Strong Buy, 8 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IKT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.40, with estimates from -$0.42 to -$0.38 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.41, with estimates from -$0.45 to -$0.37 from 5 analysts.
What revenue do analysts expect from Inhibikase Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $250000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $400000.
How many analysts cover IKT?
10 analysts rate Inhibikase Therapeutics stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
IKT pages: Overview, Earnings, Forecast, Financials, Competitors